Abbisko Completed All Patient Enrollment for The Global Phase III TGCT Trial of Its CSF-1R Inhibitor – Pimicotinib
9 April 2024 (Beijing Time), Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics) announced the completion of patient enrollment for its pivotal Phase III trial, MANEUVER (ABSK021-301) STUDY, for evaluating the efficacy and safety of pimicotinib in patients with tenosynovial giant cell tumor (TGCT)….
Transcenta Announces Collaboration with Agilent to Develop a Claudin18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial
Transcenta Holding Limited (“Transcenta”) (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, and Agilent Technologies, announce a collaboration to develop a Claudin18.2 (CLDN18.2) companion diagnostic to support TranStar301 global…
Kidney Patients Highlight Authors to Celebrate National Doctors Day
The American Association of Kidney Patients (AAKP), the largest and oldest independent kidney patient organization in the nation, is celebrating National Doctors Day by highlighting three top kidney medical experts and authors known for their tireless work as advocates for…
Former KPMG Chairman and CEO Lynne Doughtie Assumes Role as Chair of LUNGevity’s Board of Directors
LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, announced today the appointment of Lynne Doughtie, former KPMG chairman and CEO, as chair of its Board of Directors. Doughtie, who has served as a dedicated member of the LUNGevity Board since…
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, and Norgine, a leading European specialist pharmaceutical company, today announced an exclusive licensing agreement under which Norgine will commercialize PEDMARQSI® in Europe, Australia and New Zealand. PEDMARQSI is the first and only approved therapy in the…
Cedar Health Research Launches Two New Clinical Research Sites in Texas
Today, Cedar Health Research®, a multi-therapeutic independent clinical research site and patient network, officially announced two new sites in Texas located in Arlington, TX and Midland, TX. The Arlington site will now serve as the Tarrant County mid-cities hub location for Cedar Health Research’s (CHR) Dallas-Fort Worth clinical operations. Arlington…
Formosa Pharmaceuticals and AimMax Therapeutics Receive FDA Approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery
Taiwan-based Formosa Pharmaceuticals (6838.TWO) and AimMax Therapeutics (United States) announced today that the U.S. Food and Drug Administration (FDA) has approved clobetasol propionate ophthalmic suspension 0.05% (APP13007), for the treatment of post-operative inflammation and pain following ocular surgery. Utilizing…
M3 launches Doctors.net.uk: ‘Pathway’ to Support International Medical Graduates Relocating to the UK’
M3 (EU) has announced the international launch of ‘Doctors.net.uk: Pathway’, the latest addition to Doctors.net.uk, the UK’s leading online community of more than 250,000 GMC-registered doctors. M3 (EU) recently unveiled the new, exclusive online platform, which is designed to provide…
The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay’s Seladelpar in Primary Biliary Cholangitis
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that The New England Journal of Medicine (NEJM) has published detailed results from the RESPONSE Phase 3 trial evaluating seladelpar, an…
The European Commission Grants Orphan Drug Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis
NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd, announced today that the European Commission (EC) has granted orphan drug designation to NS-229, which is being developed for the treatment of the rare disease eosinophilic granulomatosis with polyangiitis (EGPA)….
